Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits.
Ayahuasca
Borderline personality disorder
Emotional dysregulation
Mindfulness
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
19
06
2018
accepted:
16
10
2018
pubmed:
9
11
2018
medline:
8
5
2019
entrez:
9
11
2018
Statut:
ppublish
Résumé
Research suggests that mindfulness-based interventions may improve mindfulness-related capacities (e.g., decentering, non-judging, and non-reacting) and emotion regulation. Previously, our group reported that ayahuasca could be a potential analogue of mindfulness practice. The main aim of the current study was to examine the effects of ayahuasca on emotional regulation and mindfulness-related capacities. Secondarily, we sought to explore the effects of ayahuasca on individuals with borderline personality disorder (BPD) traits. This is an observational study of 45 volunteers who participated in an ayahuasca session. The volunteers completed various self-report instruments designed to measure emotional dysregulation (Difficulties in Emotion Regulation Scale (DERS)) and mindfulness traits (Five Facet Mindfulness Questionnaire (FFMQ)-Short Form and Experiences Questionnaire (EQ)) prior to and 24 h after the ayahuasca session. The volunteers were divided into two subgroups based on their score on the McLean Screening Instrument for BPD (MSI-BPD). Twelve participants were grouped into the BPD-like traits subgroup while the rest of them were included in the non-BPD-like subgroup. We performed within-subjects and between-group analyses. Overall, the participants showed significant improvements on the FFMQ subscales observing, acting with awareness, non-judging, and non-reacting and also significantly improved on decentering (EQ scale) and on the DERS subscales emotional non-acceptance, emotional interference, and lack of control. The BPD-like subgroup also showed significant improvements on the DERS subscales emotional interference and lack of control but not in mindfulness capacities. These findings suggest a potential therapeutic effect for ayahuasca in emotion regulation and mindfulness capacities (including decentering, acceptance, awareness, and sensitivity to meditation practice). Based on these results, we believe that ayahuasca therapy could be of value in clinical populations, such as individuals with BPD, affected by emotion dysregulation.
Sections du résumé
BACKGROUND
BACKGROUND
Research suggests that mindfulness-based interventions may improve mindfulness-related capacities (e.g., decentering, non-judging, and non-reacting) and emotion regulation. Previously, our group reported that ayahuasca could be a potential analogue of mindfulness practice. The main aim of the current study was to examine the effects of ayahuasca on emotional regulation and mindfulness-related capacities. Secondarily, we sought to explore the effects of ayahuasca on individuals with borderline personality disorder (BPD) traits.
METHOD
METHODS
This is an observational study of 45 volunteers who participated in an ayahuasca session. The volunteers completed various self-report instruments designed to measure emotional dysregulation (Difficulties in Emotion Regulation Scale (DERS)) and mindfulness traits (Five Facet Mindfulness Questionnaire (FFMQ)-Short Form and Experiences Questionnaire (EQ)) prior to and 24 h after the ayahuasca session. The volunteers were divided into two subgroups based on their score on the McLean Screening Instrument for BPD (MSI-BPD). Twelve participants were grouped into the BPD-like traits subgroup while the rest of them were included in the non-BPD-like subgroup. We performed within-subjects and between-group analyses.
RESULTS
RESULTS
Overall, the participants showed significant improvements on the FFMQ subscales observing, acting with awareness, non-judging, and non-reacting and also significantly improved on decentering (EQ scale) and on the DERS subscales emotional non-acceptance, emotional interference, and lack of control. The BPD-like subgroup also showed significant improvements on the DERS subscales emotional interference and lack of control but not in mindfulness capacities.
CONCLUSIONS
CONCLUSIONS
These findings suggest a potential therapeutic effect for ayahuasca in emotion regulation and mindfulness capacities (including decentering, acceptance, awareness, and sensitivity to meditation practice). Based on these results, we believe that ayahuasca therapy could be of value in clinical populations, such as individuals with BPD, affected by emotion dysregulation.
Identifiants
pubmed: 30406413
doi: 10.1007/s00213-018-5085-3
pii: 10.1007/s00213-018-5085-3
doi:
Substances chimiques
Plant Preparations
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
573-580Subventions
Organisme : Instituto de Salud Carlos III
ID : PI16/00078
Références
J Psychoactive Drugs. 1999 Apr-Jun;31(2):171-7
pubmed: 10438001
Psychopharmacology (Berl). 2001 Feb;154(1):85-95
pubmed: 11292011
J Pharmacol Exp Ther. 2003 Jul;306(1):73-83
pubmed: 12660312
J Pers Disord. 2003 Dec;17(6):568-73
pubmed: 14744082
J Psychoactive Drugs. 2005 Jun;37(2):193-201
pubmed: 16149333
Assessment. 2006 Mar;13(1):27-45
pubmed: 16443717
J Abnorm Psychol. 2006 Nov;115(4):850-855
pubmed: 17100543
J Ethnopharmacol. 2007 Jul 25;112(3):507-13
pubmed: 17532158
Behav Ther. 2007 Sep;38(3):234-46
pubmed: 17697849
J Behav Med. 2008 Feb;31(1):23-33
pubmed: 17899351
Int J Drug Policy. 2008 Aug;19(4):297-303
pubmed: 18638702
Med Sci Monit. 2008 Aug;14(8):SR15-22
pubmed: 18668010
J Pers Disord. 2008 Aug;22(4):353-64
pubmed: 18684049
Science. 2009 Feb 13;323(5916):934-7
pubmed: 19213917
Behav Res Ther. 2009 May;47(5):353-8
pubmed: 19246029
J Pers Disord. 2009 Feb;23(1):20-8
pubmed: 19267659
Curr Med Chem. 2009;16(8):1017-27
pubmed: 19275609
Psychol Bull. 2009 May;135(3):495-510
pubmed: 19379027
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22468-73
pubmed: 20018732
Drug Alcohol Depend. 2010 Oct 1;111(3):257-61
pubmed: 20554400
Lancet. 2011 Jan 1;377(9759):74-84
pubmed: 21195251
J Clin Psychiatry. 2011 May;72(5):685-91
pubmed: 21658350
Psychopharmacology (Berl). 2012 Feb;219(4):1039-53
pubmed: 21842159
J Clin Psychopharmacol. 2011 Dec;31(6):717-26
pubmed: 22005052
Behav Ther. 2012 Jun;43(2):365-80
pubmed: 22440072
Personal Disord. 2011 Apr;2(2):142-50
pubmed: 22448733
Assessment. 2014 Apr;21(2):210-7
pubmed: 23344914
Clin Psychol Psychother. 2014 Jul-Aug;21(4):363-70
pubmed: 23494767
Curr Drug Abuse Rev. 2013 Mar;6(1):30-42
pubmed: 23627784
PLoS One. 2014 Jan 22;9(1):e86622
pubmed: 24466175
J Pers Disord. 2015 Feb;29(1):71-8
pubmed: 24932872
Behav Res Ther. 2014 Aug;59:40-51
pubmed: 24974307
Behav Ther. 2014 Nov;45(6):863-71
pubmed: 25311294
Braz J Psychiatry. 2015 Jan-Mar;37(1):13-20
pubmed: 25806551
Perspect Psychol Sci. 2011 Nov;6(6):537-59
pubmed: 26168376
Mol Pharmacol. 2016 Jan;89(1):142-53
pubmed: 26560551
Psychopharmacology (Berl). 2016 Mar;233(5):823-9
pubmed: 26612618
J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
Front Pharmacol. 2016 Mar 02;7:35
pubmed: 26973523
Brain Res Bull. 2016 Sep;126(Pt 1):89-101
pubmed: 26976063
Rev Psiquiatr Salud Ment. 2016 Oct - Dec;9(4):195-202
pubmed: 27067102
J Psychopathol Behav Assess. 2016 Mar;38(1):149-157
pubmed: 27231408
Mindfulness (N Y). 2016 Jun;7(3):713-726
pubmed: 27429667
Front Psychol. 2017 Feb 06;8:98
pubmed: 28220089
Int J Neuropsychopharmacol. 2017 Sep 1;20(9):698-711
pubmed: 28525587
Acta Psychiatr Scand. 2017 Sep;136(3):323-331
pubmed: 28669135
Psychiatry Res. 2017 Oct;256:403-411
pubmed: 28692921
Front Pharmacol. 2018 Mar 20;9:224
pubmed: 29615905
Psychiatry Res. 2018 Jun;264:334-339
pubmed: 29674223
J Ethnopharmacol. 1984 Apr;10(2):195-223
pubmed: 6587171
J Nerv Ment Dis. 1996 Feb;184(2):86-94
pubmed: 8596116